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Abstract
Tumor invasion and metastases represent a complex series of molecular events that portends a poor prognosis. The
contribution of inflammatory pathways mediating this process is not well understood. Nod-like receptors (NLRs) of innate
immunity function as intracellular sensors of pathogen motifs and danger molecules. We propose a role of NLRs in tumor
surveillance and in programming tumor-infiltrating lymphocytes (TILs). In this study, we examined the downstream serine/
threonine and tyrosine kinase Rip2 in a murine model of bladder cancer. In Rip2-deficient C57Bl6 mice, larger orthotopic
MB49 tumors developed with more numerous and higher incidence of metastases compared to wild-type controls. As such,
increased tumor infiltration of CD11b+Gr1hi myeloid-derived suppressor cells (MDSCs) with concomitant decrease in T cells
and NK cells were observed in Rip2-deficient tumor bearing animals using orthotopic and subcutaneous tumor models.
Rip2-deficient tumors showed enhanced epithelial-to-mesenchymal transition, with elevated expression of zeb1, zeb2, twist,
and snail in the tumor microenvironment. We found that the absence of Rip2 plays an intrinsic role in fostering the
development of granulocytic MDSCs by an autocrine and paracrine effect of granulocytic colony stimulating factor (G-CSF)
expression. Our findings suggest that NLR pathways may be a novel modality to program TILs and influence tumor
metastases.
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Introduction
The context of the immune tumor microenvironment can be
predictive of tumor stage, cancer-specific survival, as well as
response to chemotherapy [1–3]. In certain malignancies, the
presence of infiltrating CD8+ T lymphocytes correlates with
improved outcomes, whereas infiltrating B cells, CD4+ T
lymphocytes, and negative regulators including myeloid-derived
suppression cells (MDSCs) and T regulatory cells (Tregs)
negatively correlate with survival [4]. These observations under-
score the importance in defining pathways essential to program-
ming the composition of tumor infiltrating lymphocytes (TILs), as
selective modulation of the immune tumor microenvironment
represents an emerging therapeutic modality.
Pattern recognition receptors such as the prototypic Toll-like
receptor (TLR) family and intracellular nucleotide-binding oligo-
merization domain (NOD)-like receptor (NLR) family recognize
conserved motifs on pathogens as well as endogenous molecules
released by damaged cells [5]. Activation of these signaling
pathways initiates innate and adaptive immune responses, and
may promote tissue repair and regeneration. We previously
implicated TLR3 in a murine model of prostate cancer tumor
surveillance critical in programming the infiltration of T lympho-
cytes and NK cells, while suppressing Treg expansion [6]. In
bladder cancer, the efficacy of immune modulation is highlighted
by the use of intravesical Bacillus Calmette Guerin, which
promotes an influx of macrophages and neutrophils within the
tumor microenvironment mediated in part by TLR2 and 4 [7,8].
Receptor-interacting protein 2 (Rip2), a serine-threonine and
tyrosine kinase downstream and common to Nod1 and Nod2,
activates transcription factors such as NF-kB and MAP kinases
through its kinase activity as well as through recruitment of E3
ubiquitin ligase [9–14]. Rip2-dependent pathways have emerged
as critical in sensing diverse pathogens ranging from Listeria
monocytogenes, Staphylococcus aureus, and Legionella pneumophilia to
Escherichia coli as well as in mediating inflammatory disorders such
as autoimmune encephalomyelitis [15–17]. In addition, polymor-
phisms of Nod2 have been linked with susceptibility to Crohn’s
disease, while polymorphisms of Rip2 have been linked with
systemic lupus erythematosus [18,19]. The ability of NLRs to
mediate tumor surveillance has not been investigated to date.
Here, we postulate that Rip2 may mediate bladder cancer
surveillance and explore its role using a murine orthotopic and
subcutaneous bladder cancer model. We show that tumor bearing
Rip2-deficient mice biases myeloid differentiation towards the
MDSC lineage and plays an intrinsic role in the development of
the CD11b+Ly6G+Ly6Clo granulocytic MDSC population. Our
findings are the first to implicate Rip2 and NLRs in tumor
surveillance and their importance in programming the immune
tumor microenvironment. The NLR pathway may represent a
therapeutic opportunity in modulating cancer immunity to
prevent tumor invasion and metastasis.
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Materials and Methods
Ethics Statement
All animal work has been conducted in accordance with the
Public Health Service Policy on Human Care and Use of
Laboratory Animals and USDA Animal Welfare Act Regulations
through an approved UCLA Institutional Animal Care and Use
Committee protocol #2010-023-11C.
Mice
Rip2-deficient mice backcrossed to a C57Bl/6 background for
10 generations were genotyped as previously described [10]. Age-
matched C57Bl/6 mice (Jackson Laboratories) were used as
controls. Six- to 8-wk old female mice were used for the
experiments. Mice were housed in pathogen-free conditions
according to UCLA Animal Research Committee protocols.
Cell culture
MB49 cell lines (gift from Tim Ratliff) were derived from
carcinogen-induced urothelial cell carcinomas in C57Bl6 mice and
maintained at 37uC with 5% CO2 in DMEM (Cellgro),
supplemented with 10% FBS (Omega Scientific) and 1% penicillin
and streptomycin [20].
Tumor models
For intravesical tumor implantation, female mice were sedated,
catheterized with a 24 gauge catheter (BD Biosciences), and
instilled with 10 mg of poly-L-lysine (Sigma) in 100 ml for 30
minutes before drainage and instillation of 26106 MB49 cells in
100 ml for 60 minutes [21,22]. Mice were sacrificed 12 days
following tumor inoculation, and the bladder and internal organs
were examined. Bladder, lungs, and kidneys were fixed in formalin
or embedded in OCT for staining by H&E or immunofluores-
cence [23]. Pulmonary and renal metastases were determined
grossly and by light microscopy of H&E sections in a single
representative coronal cross section. For subcutaneous tumor
challenges, 56105 MB49 cells were implanted subcutaneously in
the flanks of mice with tumor growth monitored every other day.
Following sacrifice of the mice 14 days following tumor
inoculation, tumors were harvested, weighed, and dissociated for
analysis.
Immunofluorescence and Immunohistochemistry
Immunofluorescence was performed on OCT-embedded frozen
tissue sections. Sections were blocked with 10% goat serum and
10% BSA in PBS for 1 hour at RT, incubated with primary
antibody overnight at 4uC, then washed and incubated with Al-
448 or Al-466 goat anti-rat secondary antibody (Invitrogen) at
1:800 dilution. Immunohistochemistry was performed on forma-
lin-fixed paraffin-embedded tumor sections. Sections were subject
to heated antigen unmasking solution for 30 minutes, quenched in
0.3% hydrogen dioxide in PBS for 15 minutes, blocked with 10%
goat serum and 10% BSA in PBS for 1 hour at RT, then
incubated with primary antibody overnight at 4uC, incubated with
biotinylated goat anti-rat secondary antibody at 1:800 dilution for
30 minutes at RT, and developed using the ABC kit (Vector Labs).
Slides were counterstained with hematoxylin. Sections were
mounted with Vectorshield and analyzed by fluorescence or light
microscopy (Zeiss). Antibodies include CD11b (M1/70, R&D
Systems), CD4 (RM4–5, Biolegend), CD8 (53.6–7, R&D Systems),
CD49b (DX-5, Biolegend), Foxp3 (FJK-16s, eBioscience), Ly6G
(RB6-BC5, eBioscience), Ly6C (AL-21, BD Biosciences), E-
Cadherin (MAB7481, R&D Systems), N-cadherin (H-63, Santa
Cruz Biotechnology), and phospho-IkBa (Ser 32/36, #9246, Cell
Signaling).
Cytokine array
An inflammatory cytokine array comparing serum from wild-
type and Rip2-deficient mice implanted with intravesical MB49
cells was performed as described (ARY006, R&D Systems).
Flow cytometry analysis
Single-cell suspensions prepared from spleens, dissociated tumor
cells, or differentiated bone marrow cells were analyzed by flow
cytometry. Antibodies including CD4 (RM-4), CD8 (53–67),
NK1.1 (pk-136), B220 (RA3-6B2), CD11b (M1/70), CD45.2
(104), Gr1 (RB6-8C5), Ly-6G (1A8), and Ly-6C (AL21) were
obtained from BD Biosciences. Data acquisition was performed on
a FACS LSRII (BD Biosciences) and analyzed using FlowJo.
Bone marrow-derived myeloid differentiation
BM-derived cells were obtained by flushing femurs and tibia
from C57Bl/6 wild-type and RIP22/2 mice. Following lysis of red
blood cells with ACK buffer, the remaining cells were cultured in
DMEM supplemented with 10% FBS and 20% L929 cell-
conditioned media. After incubation for 24 hours, non-adherent
cells were harvested and plated at 26105 cells/mL in DMEM
supplemented with 10% fetal calf serum, 50 mM 2-mercaptoeth-
anol, 10 mM HEPES, 1 mM sodium pyruvate, 1% penicillin and
streptomycin, and supplemented using 20% L929 with 40 ng/mL
G-CSF (Biolegend), 40 ng/mL GM-CSF (Invitrogen), or in
combination. Cultures were incubated at 37uC with 5% CO2
for 3 days. On Day 3, fresh medium with appropriate cytokines
was added. On Day 4 cultured cells were harvested for FACS.
Isolation of tumor-infiltrating immune cells
Tumor tissue was minced in PBS with sterile scissors to
approximately 1 mm pieces and digested in 0.25% collagenase IV
in DMEM supplemented with 10% FBS at 37uC with 5% CO2 for
3 hours [24]. Cell suspensions were filtered through a 70 mm cell
strainer, subjected to ACK buffer for 5 minutes on ice, and then
filtered through a 20 mM cell strainer for flow cytometry. Cells
sorted using a FACS Aria (BD Biosciences) into
CD45+CD11b+Gr1hi, CD45+CD11b+GR1lo, and CD452 frac-
tions were collected for qPCR.
Quantitative RT-PCR
Total RNA extracted from sorted cells and fresh frozen bladder
tumor as described (RNeasy Mini Kit, Qiagen) was used to
synthesize cDNA using High Capacity cDNA Reverse Transcrip-
tion Kits (Applied Biosystems). Relative gene expression was
determined using SYBR Green PCR Master Mix (Applied
Biosystems). A Bio-Rad iCycler was used to analyze the samples
while the comparative threshold cycle method was used to
calculate gene expression normalized to GAPDH as a gene
reference. Primers sets for the following genes were used:
Arginase-1, 59-AGAGATACTTCCAACTGCCAGACT, 39-AC-
CTGGCCTTTGTTGATGTCCCTA; iNOS, 59-
GCTGGAAGCCACTGACACTTCG, 39-CGAGATGGT-
CAGGGTCCCCT; IL-4, 59- GTCATCCTGCTCTTCTTTC,
39- ATGGCGTCCCTTCTCCTGT; IL-10, 59-GCTCTTACT-
GACTGGCATGAG, 39-CGCAGCTCTAGGAGCATGTG; IL-
12 p40, 59- TGGTTTGCCATCGTTTTGCTG, 39- ACAGGT-
GAGGTTCACTGTTT; IFNc, 59- GGATGCATTCATGAG-
TATTGC, 39- CCTTTTCCGCTTCCTGAGG; M-CSF, 59-
AGGACCTGTTGGAGTTCCCTC, 39- TTTCGCCCTCA-
Rip2 in MDSCs and Bladder Cancer Metastasis
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CACTTGATGA; G-CSF, 59- CTCAACTTTCTGCCCA-
GAGG, 39- AGCTGGCTTAGGCACTGTGT; GM-CSF, 59-
GCCATCAAAGAAGCCCTGAA, 39- GCGGGTCTGCACA-
CATGTTA; Zeb1, 59-AACGGAGATTTGTCTCCCAGT, 39-
CTGTCCAGCTTGCATCTTTTC; Zeb2, 59-TAGCCGGTC-
CAGAAGAAATG, 39-GGCCATCTCTTTCCTCCAGT; Snail,
59-GCGGAAGATCTTCAACTGCAAATATTGTAAC, 39-
GCAGTGGGAGCAGGAGAATGGCTTCTCAC; Twist, 59-
CGGGTCATGGCTAACGTG, 39-CAGCTTGCCATCTTG-
GAGTC; and GAPDH, 59-GACCCCTTCATTGACCTCAAC,
39-CTTCTCCATGGTGGTGAAGA.
Results
To investigate the role of Rip2 in tumor surveillance, we
challenged wild-type and Rip2-deficient mice with syngeneic
MB49 cells in an orthotopic bladder cancer model. We observed
an almost two-fold increase in tumor weight in the absence of Rip2
(Fig 1A). Tumors harvested from mice of both genotypes
demonstrated evidence of invasion into the detrusor muscle by
H&E staining under light microscopy with larger tumors seen in
Rip2-deficient animals (Fig 1B). Gross and histologic examination
of internal organs revealed a greater number of metastasis in the
lungs and kidneys of Rip2-deficient mice at an approximately
three-fold and two-fold higher incidence respectively over wild-
type controls (Fig 1C–D). No other gross metastases were observed
including in the liver.
We have previously implicated Rip2 in development of Th1 and
NK cells [10], while others reported a role in dendritic cell
infiltration [17]. To investigate the role of Rip2 in the context of
tumorigenesis, bladder tumor TILs were examined by immuno-
fluorescence and immunohistochemistry. This revealed decreased
infiltration of CD8+ T lymphocytes, CD4+ T lymphocytes, and
NK cells in the absence of Rip2 as predicted. Examination of
Foxp3+ cells representative of T regulatory cells, showed an
increasing trend in Rip2-deficient mice compared to wild-type
mice although it did not reach statistical significance. Interestingly,
tumors showed increased infiltration of CD11b+ myeloid cells in
Rip2-deficient compared to wild-type mice, while additional
characterization of this myeloid population showed an expected
increase in the macrophage marker F4/80 and in the Gr-1
subtype Ly6G, but not subtype Ly6C in tumors from Rip2-
deficient mice (Fig 2).
To further examine the function of the tumor infiltrating
populations, we subcutaneously implanted MB49 cells to generate
larger tumors to facilitate subsequent sorting of cells. Similarly to
orthotopic tumors, subcutaneous tumors developed in Rip2-
deficient mice were of increased size compared to wild-type
Figure 1. Increased tumor size and metastases in Rip2-deficient mice. Rip2+/+ and Rip22/2 mice intravesically implanted with MB49 cells and
sacrificed at 12 days were assessed for bladder tumor (A) weight, (B) histology with H&E staining at x5 and x20 magnification. C, Lungs were
examined for metastasis by number of metastatic lesions per coronal cross section, % incidence, histology with H&E staining at x10 and x40
magnification, and gross examination. D, Kidneys were examined for metastasis by number of metastatic lesions per coronal cross section, %
incidence, and histology with H&E staining at x5 and x20 magnification. Representative examples are shown. Columns, mean of 33 Rip2+/+ and 19
Rip22/2 mice pooled from 5 independent experiments; bars, SEM. All p values were determined by two-tailed Student’s t test, with statistically
significance defined as p,0.05.
doi:10.1371/journal.pone.0094793.g001
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counterparts (Fig 3A). Dissociated tumors sorted for
CD45+NK1.1+ NK cells showed decreased numbers in Rip2-
deficient compared to wild-type mice as expected (Fig 3B). The
infiltrating numbers of CD4 and CD8 cells were too small to
quantitate by flow cytometry (data not shown). Consistent with the
previous orthotopic tumors, dissociated subcutaneous tumors
sorted for surface markers CD11b+ and Gr1+ showed enriched
numbers of CD11b+Gr1hi cells from Rip2-deficient compared to
wild-type mice (Fig 3C). To further examine the functional
characteristics of the CD11b+Gr1hi cells, we examined a panel of
genes that represent a signature of MDSCs and myeloid
subpopulations. Arginase-1 and iNOS mediate the T suppressive
effects of MDSCs [25]. IFNc supports the differentiation towards
M1 cells, distinguished in turn by secretion of IL-12. IL-4 polarizes
myeloid precursors towards a M2 phenotype, which is strongly
associated with tumor associated MDSCs and express IL-10 to
mediate their immune suppressive effects [26]. We show that
Rip2-deficient CD11b+Gr1hi cells expressed higher levels of
arginase-1 compared to cells from wild-type mice, with a similar
trend in iNOS expression (Fig 3D). Consistently, increased IL-10
expression in Rip2-deficient CD11b+Gr1hi cells compared to cells
from wild-type controls were observed, while no significant
differences were seen in expression of IFNc and IL-12, indicative
of M2 polarization (Fig 3D). Levels of IL-4 were undetectable in
the CD11b+Gr1hi cells (data not shown).
To examine the Rip-2-dependent systemic cues that may
influence the development of the tumor microenvironment,
cytokine levels were measured using an inflammatory cytokine
array comparing serum from wild-type and Rip2-deficient mice
implanted with orthotopic MB49 bladder tumors. The levels of
seven cytokines from the panel comprising 40 cytokines were
found elevated in the absence of Rip2. The majority were
associated with myeloid differentiation and chemotaxis, including
G-CSF, M-CSF, IL-16, MCP-1, TREM-1, TIMP-1, and IL-1a
with relative levels shown schematically [27–33] (Fig 4A). Sple-
nocytes from tumor bearing mice were analyzed to assess the
influence of these cytokine alterations, revealing no significant
differences in the numbers of CD4+ and CD8+ T lymphocytes,
B220+ B lymphocytes, and NK1.1+ cells, but increased develop-
ment of CD11b+Ly6Ghi cells in Rip2-deficient compared to wild-
type mice, that represent the granulocytic MDSC population
(Fig 4B). To further examine the bladder tumor microenviron-
ment, we examined a panel of cytokines that influence the
functional polarization of macrophages as well as differentiation of
MDSCs in the intravesical bladder tumors [34]. Increased levels of
IL-4, G-CSF, and GM-CSF were observed in bladder tumors
from Rip2-deficient compared to wild-type mice, while no
differences were detected in IFNc and M-CSF expression,
consistent with a tumor microenvironment fostering development
of the tumor associated MDSCs (Fig 4C). To discriminate between
cytokine production from tumor and surrounding stroma to the
myeloid populations, we examined G-CSF expression in the
CD452 population representing tumor and stromal cells, and
CD11b+Gr1hi population representing myeloid cells, and showed
increased G-CSF in Rip2-deficient compared to wild-type
Figure 2. Loss of Rip2 alters composition of tumor infiltrating cells from Rip2-deficient mice. Infiltration of CD8, CD4, NK, CD11b, F4/80,
Ly6G, and Ly6C expressing cells as indicated, were examined by immunofluorescence, and Foxp3 by immunohistochemistry in bladder tumors from
Rip2+/+ and Rip22/2 mice intravesically implanted with MB49 cells and sacrificed at 12 days. Left panels show specific antibody staining, middle panel
shows DAPI staining, right panel shows merging of antibody and DAPI stains. Representative examples from each group of four to six mice in 4
independent experiments are shown at x40 magnification. Bar graphs enumerate mean number of cells per x40 field of 3 representative sections
from groups of four mice; bars, SD. All p values were determined by two-tailed Student’s t test, with statistically significance defined as p,0.05.
doi:10.1371/journal.pone.0094793.g002
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CD11b+Gr1hi cells, suggesting an autocrine and paracrine
regulation of MDSCs in absence of Rip2 (Fig 4D).
The MDSC population is comprised of immature myeloid cells
and myeloid cell progenitors that can differentiate into mature
macrophages, granulocytes, and dendritic cells. They are charac-
terized by T lymphocyte suppressive ability and expression of
arginase-1 and iNOS [25]. In the mouse, they can be further
distinguished into granulocytic MDSCs by expression of surface
markers CD11b+Gr1hi or CD11b+Ly6G+Ly6Clo and monocytic
MDSCs by expression of markers CD11b+Gr1lo or CD11b+Ly6-
GloLy6Chi [35]. To test the intrinsic role of Rip2 in myeloid
development, naı¨ve bone marrow from wild-type and Rip2-
deficient mice were subject to in vitro differentiation using M-CSF,
G-CSF, GM-CSF, or G-CSF and GM-CSF for 4 days and
examined for expression of CD11b, Ly6G, and Ly6C. In the
presence of G-CSF, GM-CSF, and G-CSF plus GM-CSF, the
absence of Rip2 resulted in a bias towards the CD11b+Ly6-
G+Ly6Clo granulocytic MDSC population (Fig 5A). In BM-
derived MDSCs differentiated using G-CSF or G-CSF and GM-
CSF, increased arginase-1 and iNOS expression was uniformly
observed in Rip2-deficient compared to wild-type cells, consistent
with the increased development of MDSCs (Fig 5B).
MDSCs have been implicated in promoting EMT, a process
critical in facilitating tumor invasion and subsequent tumor
metastases [36]. A hallmark of EMT is a switch in surface
adhesion markers with the loss of E-cadherin and expression of N-
cadherin [37]. To investigate the influence of Rip2 in development
of EMT, we examined expression of adhesion markers in
intravesical tumors and observed decreased E-cadherin expression
throughout the tumor with concomitant increased N-cadherin
expression at the peripheral of the tumor in Rip2-deficient relative
to wild-type mice (Fig 6A). NF-kB activation has been implicated
in promoting EMT and thus we examined its activation in the
absence of Rip2 [38]. Consistent with prior literature, we observed
decreased canonical NF-kB activation exhibited by decreased p-
IkB expression in Rip2-deficient tumors (Fig 6B), suggesting NF-
kB independent mechanisms to account for EMT [39]. To
investigate other mechanisms promoting EMT, a panel of
transcription factors involved in EMT including zeb-1, zeb-2, snail,
and twist were examined in tumor and stromal cells from
dissociated subcutaneous tumors depleted of CD45, with the
expression of zeb-1, zeb-2, and snail found increased in Rip2-
deficient compared to wild-type tumor bearing mice, and
increased expression of twist approaching statistical significance
(Fig 6C). We also examined expression of these EMT inducing
genes in lungs containing metastases from Rip2 wild-type and –
deficient mice, revealing a similar trend with statistical significance
for increased twist expression in absence of Rip2 (Fig 6D).
Figure 3. Increased tumor infiltrating granulocytic MDSCs in Rip2-deficient mice. Rip2+/+ and Rip22/2 mice subcutaneously implanted
with MB49 cells for 14 days were assessed for (A) tumor weight, and sorted by flow cytometry to examine (B) CD45+NK1.1+ cells, and (C)
CD45+CD11b+Gr1hi and CD45+CD11b+Gr1lo cells. Column, mean of four mice; bars SD. Data are representative of two independent experiments. D,
Sorted CD45+CD11b+Gr1hi and CD45+CD11b+Gr1lo cells in Rip2+/+ and Rip22/2 mice were examined for expression of arginase-1 and iNOS by qPCR,
while CD45+CD11b+Gr1hi cells in Rip2+/+ and Rip22/2 mice were examined for expression of IL10, IL-12, and IFNc by qPCR. Column, mean of two
mice; bars SD. Data are representative of three independent experiments. Representative examples are shown. All p values were determined by two-
tailed Student’s t test, with statistically significance defined as p,0.05.
doi:10.1371/journal.pone.0094793.g003
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Discussion
The immune composition of the tumor microenvironment can
be predictive of disease-free and overall survival. This has been
shown in the context of CD4+ T lymphocytes and CD1a dendritic
cells in axillary lymph nodes correlating with disease-free survival
in breast cancer patients [40], to tumor-infiltrating CD3+ cells and
CD8+ T lymphocytes in colon [1] and bladder cancer respectively
[2]. The balance of TILs may refine the predictive ability of the
immune microenvironment, as CD4luCD48luCD8hi patients
exhibited improved recurrence-free survival while the ratio of
CD8+ T cells to CD68+ tumor associated macrophages predicted
overall survival and response to neoadjuvant chemotherapy in
breast cancer patients [3]. Anti-tumor immunity may be
augmented by targeting negative regulators of T cell co-
stimulation as evidenced by the development of anti-CTLA4
and anti-PD1 therapeutics, and may be extended to targeting
Tregs and MDSCs [41]. This evidence suggests that active
programming of the tumor immune microenvironment may be a
viable strategy to harness and bias immunity towards an anti-
tumor response.
We have hypothesized that the ability of PRRs to sense
contextual signals from pathogens to initiate an immune response
is paralleled by the ability of DAMPs released by cellular damage
in the tumor environment to shape tumor immunity. NLRs
including Nod1 and Nod2 have been implicated in sensing various
pathogens as well as cellular stresses [42]. The role of cytosolic
PRRs, such as the NLR family in tumor surveillance is unclear.
Recently, loss of Rip2 has been implicated in development of
larger colorectal cancers in a murine model [43]. In this
manuscript, we show that NLRs through Rip2 signaling can
shape the tumor microenvironment towards tumor-infiltrating
CD8+ T lymphocytes, NK cells, and suppression of MDSCs.
Similarly, in the absence of Rip2, larger orthotopic bladder tumors
developed as well as increased tumor metastases in both the lung
and kidneys.
Figure 4. Biased development of granulocytic MDSCs in Rip2-deficient mice. A, Inflammatory cytokine expression in serum of Rip2+/+ and
Rip22/2 mice intravesically implanted with MB49 cells for 12 days was assessed by cytokine array analysis. Cytokines increased in Rip22/2 mice are
depicted in the schematic as shown. (+) 2-5x, (++) 5-10x, (+++) .10x based on quantitation by ImageJ. Results are from duplicates and representative
of two independent experiments. B, Splenocytes from Rip2+/+ and Rip22/2 mice were examined for expression of CD4, CD8, B220, NK1.1, while
CD11b+ cells were examined for expression of Ly6G and Ly6C by flow cytometry as indicated. Column, mean of four mice; bars SD. Data are
representative of two independent experiments. C, Total tumor from Rip2+/+ and Rip22/2 mice intravesically implanted with MB49 cells and sacrificed
at 12 days were examined for expression of IL4, IFNc, M-CSF, G-CSF, and GM-CSF by qPCR. Column, mean of three mice; bars SD. D, Tumors from
Rip2+/+ and Rip22/2 mice subcutaneously implanted with MB49 cells for 14 days were fractioned to CD452 and CD45+CD11b+Gr1hi cells and
examined for G-CSF expression by qPCR. Column, mean of three mice; bars SD. All p values were determined by two-tailed Student’s t test, with
statistically significance defined as p,0.05.
doi:10.1371/journal.pone.0094793.g004
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Rip2 was initially described based on sequence homology to its
C-terminal CARD domain [44]. We developed Rip2-deficient
animals and described a role in innate immunity implicating Rip2
downstream of Nod1, and adaptive immunity mediating IFNc
responses in Th1 and NK development [10]. Since then, the
importance of Rip2 in NLR signaling and macrophage function
has been validated and shown to play a critical role in innate
immune signal transduction of Nod1 and Nod2 receptors [45]. In
the absence of tumor growth, we found no significant differences
in the development of all splenocytic lineages examined including
CD11b+Gr1+ cells in Rip2-deficient compared to wild-type mice.
However, in the presence of tumor growth we observed increased
splenocytic CD11b+Ly6G+ cells representing granulocytic MDSCs
in the absence of Rip2 [35].
We examined the systemic macroenvironment as well as local
microenvironment levels of cytokines that were altered by the
absence of Rip2 expression. Interestingly, elevated serum
cytokines important in myeloid differentiation were found in
Rip2-deficient tumor bearing animals, with increased levels of G-
CSF and M-CSF, as well as MCP-1 and TREM-1. MCP-1 has
been implicated in higher recurrence and worse bladder cancer
prognosis by mediating tumor invasion, while TREM-1 has been
implicated in activation of Kuffner cells in hepatocellular
carcinoma [27,30]. Within the tumor microenvironment, in the
absence of Rip2, we found a cytokine signature enriched in IL-4
and G-CSF, polarizing towards a M2 phenotype as reflected in
increased production of IL-10 and arginase-1 [46]. M2 macro-
phages have been associated with tumor progression as well as
MDSC development [47].
Examining the tumor infiltration population, we found not only
increased proportion of CD11b+Gr1hi cells in Rip2-deficient
animals, but also increased expression of arginase-1 and iNOS,
which leads to inhibition of T cells and NK cells, and suggests an
intrinsic function of Rip2 in MDSC development. Rip2-deficient
CD11b+Gr1hi MDSCs produced elevated levels of IL-10 which
may further inhibit T cell activity by enhancing Tregs [48]. With
the increased activation of Rip2-deficient MDSCs, we asked
whether Rip2 plays an intrinsic role in the development of
CD11b+ subsets. Bone marrow-derived MDSCs using various
cytokines showed increased development of CD11b+Ly6G+Ly6Clo
granulocytic MDSCs in the presence of G-CSF, GM-CSF, or their
combination in Rip2-deficient compared to wild type cells, while
there was no increased development of monocytic MDSC. The
increased serum production of G-CSF as well as an intrinsic
development of granulocytic MDSCs in vitro in response to G-CSF,
suggests a mechanism for increased granulocytic MDSCs in the
absence of Rip2.
Growing evidence has attributed MDSCs in cancer progression
to immune suppression and modifying the microenvironment to
foster tumor metastasis. Increased MDSCs have been described in
cancer patients, including patients with bladder cancer [49,50].
Granulocytic MDSCs predominate in TIL populations and
suppress CD8+T cells by producing reactive oxidative species
(ROS), Arg1, and iNOS [25,35]. Recent studies support the role of
granulocytic MDSCs to induce EMT in a melanoma model
mediated by the chemokine receptor expressed on MDSCs,
CXCR2 [36]. During metastasis, it is essential that cancer cells
acquire a motile phenotype that allows for tumor invasion,
extravasation into the blood stream or lymphatic channels for
dissemination, followed by tumor implantation and growth. We
noted increased tumor infiltrating MDSCs, decreased T lympho-
cytes and NK cells, and larger tumors with substantially higher
numbers and rates of pulmonary metastases. With the observed
increased metastasis in Rip2-deficient mice, we examined tumors
Figure 5. Intrinsic enhanced development of MDSC in absence of Rip2. A, Bone marrow from naı¨ve Rip2+/+ and Rip22/2 mice were
differentiated by M-CSF, G-CSF, GM-CSF, and G-CSF plus GM-CSF as indicated for four days prior to flow cytometry to examine expression of Ly6G and
Ly6C in CD11b+ cells (ranging from 70–90%, not shown). CD11b+LyG+Ly6Clo and CD11b+LyGloLy6Chi populations for each group are shown as total
cell counts per 105 starting BM cells. B, Expression of arginase-1 and iNOS by qPCR in G-CSF and G-CSF plus GM-CSF differentiated bone marrow from
naı¨ve Rip2+/+ and Rip22/2 mice. Column, mean of three mice; bars SD. Data are representative of two independent experiments. Representative
examples are shown. All p values were determined by two-tailed Student’s t test, with statistically significance defined as p,0.05.
doi:10.1371/journal.pone.0094793.g005
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for features of EMT and demonstrated cadherin switching by loss
of E-cadherin expression and gain of N-cadherin expression at the
tumor periphery. We also showed increased tumoral expression of
EMT transcription factors including zeb-1, zeb-2, and snail. NF-kB
has been implicated in enhancing EMT, so the decreased
activation in Rip2-deficient animals suggests an NF-kB-indepen-
dent mechanism [38]. We found elevated levels of TIMP-1 in
Rip2-deficient animals, which has been implicated in inducing
expression of slug, twist, zeb1 and zeb2 [33]. A recent report
describing down regulation of E-cadherin expression by Rip2
knockdown in vitro supports our findings [39]. These data support a
local-regional shift in the tumor microenvironment enhanced by
loss of Rip2 to facilitate EMT.
In humans, mutations in Nod2 are associated with Crohn’s
disease, while mutations in the Rip2 locus are linked with systemic
lupus erythematosus [18,19]. These inflammatory diseases have
been associated with susceptibility to cellular stress signals as well
as pathogens in the gut flora. Our findings showing increased
MDSCs in the absence of Rip2 appear seemingly contradictory.
However, the development of MDSCs is not clear. Potentially, the
activation of tumor associated MDSCs may be triggered in the
context of endogenous ligands exposed during tumorigenesis.
These contextual signals may differ from other endogenous or
pathogen-related signals that bias immune activation. Endogenous
ligands expressed either from normal cells or specific to
transformed cells that mediate these contextual signals for NLRs
have yet to be identified and remain the subject of future
investigations.
In the absence of Rip2, pathologic conditions such as the
development of cancer, lead to microenvironment alterations and
intrinsic activation of myeloid progenitors that expand the
granulocytic MDSC population. These changes may influence
EMT and development of metastases. Current therapeutic
strategies have targeted negative T cell regulators. This includes
utilizing anti-CTLA4 and anti-PD1 antibody therapies, or
targeting MDSCs by inhibition of CSF-1R. The use of PRR
modulation may be a novel strategy to program the TIL to favor
anti-tumor immunity. This may be adopted on its own, or in
conjunction with antigen-specific targeted therapy. The differences
we have observed within the tumor microenvironment in our
models of various PRR signaling mediator knockouts suggest that
modulation of PRRs may need to be tailored to specific diseases
and disease states. Our data suggest that TILs can by further
shaped by activation of NLRs and function as immune modulators
or adjuvant therapies.
Figure 6. Enhanced epithelial-to-mesenchymal transition in tumors from Rip2-deficient mice. A, Rip2+/+ and Rip22/2 mice intravesically
implanted with MB49 cells for 12 days were assessed for E-cadherin and N-cadherin expression by immunofluorescence. Magnification of x40. Data
are representative of two independent experiments. B, Bar graphs below enumerate mean number of cells per x40 field of 3 representative sections
from groups of four mice; bars, SD. C, Expression of zeb-1, zeb-2, snail, and twist were examined from CD452 dissociated total tumor tissue by qPCR.
Column, mean of four mice; bars SD. Data are representative of two independent experiments. D, Expression of zeb-1, zeb-2, snail, and twist were
examined from dissociated lungs containing metastases by qPCR. Column, mean of four mice; bars SD. All p values were determined by two-tailed
Student’s t test, with statistically significance defined as p,0.05.
doi:10.1371/journal.pone.0094793.g006
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In summary, we provide the initial evidence that intracellular
NLRs represented by Rip2 can program the immune microen-
vironment and influence tumor invasion and metastasis in a
bladder cancer model. We support a novel role of Rip2 in the
development and recruitment of granulocytic MDSCs and
highlight the contribution of MDSCs to the development of
metastases in bladder cancer. Further study will be needed to
clarify the contextual signals that trigger NLRs to mediate these
functions. This study adds credence to our hypothesis that NLRs
are critical sensors for the programming of the tumor immune
microenvironment.
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